Skip to main content
Erschienen in: Archives of Gynecology and Obstetrics 4/2011

01.04.2011 | Gynecologic Oncology

Complete lymph node dissection: is it essential for the treatment of borderline epithelial ovarian tumors?

verfasst von: Mine Kanat-Pektas, Mustafa Ozat, Tayfun Gungor, Izzet Sahin, Hakan Yalcin, Bulent Ozdal

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Abstract

Objective

The present study aims to compare the clinical and reproductive outcomes of women who have undergone lymph node dissection with those who have not and to discuss the indications for retroperitoneal evaluation in the treatment of borderline ovarian tumors.

Methods

The present study investigated 123 women who were finally diagnosed with borderline epithelial ovarian tumors at the study center between January 1999 and January 2009. A total of 68 patients (55.3%) were found to have a complete surgical staging procedure.

Results

The patients who underwent complete lymph node dissection were significantly younger than those who did not have lymphadenectomy. Thus, the ratio of postmenopausal women was significantly higher among those in whom retroperitoneal evaluation was performed. As expected, the intraoperative blood loss was significantly more and the hospital stay was significantly longer in patients who underwent complete lymph node dissection. Also, the non-serous borderline ovarian tumors were significantly more frequent in the latter patient group. However, overall and disease-free survival spans were found to be statistically similar for both study groups as well as the recurrence rate.

Conclusions

Retroperitoneal evaluation can be spared in every woman with borderline ovarian tumor unless she is to undergo complete surgical staging procedure because of high recurrence risk, advanced stage disease or personal choice.
Literatur
2.
Zurück zum Zitat Seidman JD, Ronnett BM, Kurman RJ (2002) Pathology of (low malignant potential) ovarian tumors. Best Pract Res Clin Obstet Gynaecol 16(4):499–512PubMedCrossRef Seidman JD, Ronnett BM, Kurman RJ (2002) Pathology of (low malignant potential) ovarian tumors. Best Pract Res Clin Obstet Gynaecol 16(4):499–512PubMedCrossRef
3.
Zurück zum Zitat Ohta T, Ohmichi M, Hayasako T, Snitoh M, Kojimahara T, Kawagee J, Nakahara K, Motoyama T, Kurachi H (2005) Characteristic features of ovarian borderline tumors with invasive implant. Arch Gynecol Obstet 272(4):278–282PubMedCrossRef Ohta T, Ohmichi M, Hayasako T, Snitoh M, Kojimahara T, Kawagee J, Nakahara K, Motoyama T, Kurachi H (2005) Characteristic features of ovarian borderline tumors with invasive implant. Arch Gynecol Obstet 272(4):278–282PubMedCrossRef
4.
Zurück zum Zitat Silverberg SG, Bell DA, Kurman RJ et al (2004) Borderline ovarian tumors: key points and workshop summary. Hum Pathol 35(8):910–917PubMedCrossRef Silverberg SG, Bell DA, Kurman RJ et al (2004) Borderline ovarian tumors: key points and workshop summary. Hum Pathol 35(8):910–917PubMedCrossRef
5.
Zurück zum Zitat Gershenson DM (2002) Clinical management of potential tumors of low malignancy. Best Pract Res Clin Obstet Gynaecol 16(4):513–527PubMedCrossRef Gershenson DM (2002) Clinical management of potential tumors of low malignancy. Best Pract Res Clin Obstet Gynaecol 16(4):513–527PubMedCrossRef
6.
Zurück zum Zitat Jaffe E, Harris N, Stein H, Vardiman J (2003) WHO classification of tumours-pathology and genetics of tumours of the breast and female genital organs. IARC Press, Lyon Jaffe E, Harris N, Stein H, Vardiman J (2003) WHO classification of tumours-pathology and genetics of tumours of the breast and female genital organs. IARC Press, Lyon
7.
Zurück zum Zitat Sherman ME, Mink PJ, Curtis R et al (2004) Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis. Cancer 100(5):1045–1052PubMedCrossRef Sherman ME, Mink PJ, Curtis R et al (2004) Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis. Cancer 100(5):1045–1052PubMedCrossRef
8.
Zurück zum Zitat Yavuzcan A, Baloglu A, Cetinkaya B (2009) The investigation of the factors affecting retroperitoneal lymph node metastasis in stage IIIC and IV epithelial ovarian cancer. Arch Gynecol Obstet 280(6):939–944PubMedCrossRef Yavuzcan A, Baloglu A, Cetinkaya B (2009) The investigation of the factors affecting retroperitoneal lymph node metastasis in stage IIIC and IV epithelial ovarian cancer. Arch Gynecol Obstet 280(6):939–944PubMedCrossRef
9.
Zurück zum Zitat Rao GG, Skinner E, Gehrig PA, Duska LR, Coleman RL, Schorge JO (2004) Surgical staging of ovarian low malignant potential tumors. Obstet Gynecol 104(2):261–266PubMedCrossRef Rao GG, Skinner E, Gehrig PA, Duska LR, Coleman RL, Schorge JO (2004) Surgical staging of ovarian low malignant potential tumors. Obstet Gynecol 104(2):261–266PubMedCrossRef
10.
Zurück zum Zitat Pirimoglu ZM, Afsin Y, Guzelmeric K, Yilmaz M, Unal O, Turan MC (2008) Is it necessary to do retroperitoneal evaluation in borderline ovarian tumors? Arch Gynecol Obstet 277:411–414PubMedCrossRef Pirimoglu ZM, Afsin Y, Guzelmeric K, Yilmaz M, Unal O, Turan MC (2008) Is it necessary to do retroperitoneal evaluation in borderline ovarian tumors? Arch Gynecol Obstet 277:411–414PubMedCrossRef
11.
Zurück zum Zitat Yoshinaka A, Fukusawa I, Sakamoto T, Tanaka M, Ota Y, Inabe N (2000) The fertility and pregnancy outcomes of the patients who underwent preservative operation followed by adjuvant chemotherapy for malignant ovarian tumors. Arch Gynecol Obstet 264(3):124–127PubMedCrossRef Yoshinaka A, Fukusawa I, Sakamoto T, Tanaka M, Ota Y, Inabe N (2000) The fertility and pregnancy outcomes of the patients who underwent preservative operation followed by adjuvant chemotherapy for malignant ovarian tumors. Arch Gynecol Obstet 264(3):124–127PubMedCrossRef
12.
Zurück zum Zitat Chan JK, Lin YG, Loizzi V, Ghobriel M, DiSaia PJ, Berman ML (2003) Borderline ovarian tumors in reproductive-age women. Fertility-sparing surgery and outcome. J Reprod Med 48:756–760PubMed Chan JK, Lin YG, Loizzi V, Ghobriel M, DiSaia PJ, Berman ML (2003) Borderline ovarian tumors in reproductive-age women. Fertility-sparing surgery and outcome. J Reprod Med 48:756–760PubMed
13.
Zurück zum Zitat Jones MB (2006) Borderline ovarian tumors: current concepts for prognostic factors and clinical management. Clin Obstet Gynecol 49:517–525PubMedCrossRef Jones MB (2006) Borderline ovarian tumors: current concepts for prognostic factors and clinical management. Clin Obstet Gynecol 49:517–525PubMedCrossRef
14.
Zurück zum Zitat Boriboonhirusam D, Sermboon A (2004) Accuracy of frozen section in the diagnosis of malignant ovarian tumor. J Obstet Gyneacol Res 30:394–398CrossRef Boriboonhirusam D, Sermboon A (2004) Accuracy of frozen section in the diagnosis of malignant ovarian tumor. J Obstet Gyneacol Res 30:394–398CrossRef
15.
Zurück zum Zitat Boran N, Cil AP, Tulunay G (2005) Fertility and recurrence results of conservative surgery for borderline ovarian tumors. Gynecol Oncol 97:845PubMedCrossRef Boran N, Cil AP, Tulunay G (2005) Fertility and recurrence results of conservative surgery for borderline ovarian tumors. Gynecol Oncol 97:845PubMedCrossRef
16.
Zurück zum Zitat Trimble CL, Trimble EL (2003) Ovarian tumors of low malignant potential. Oncology (Huntingt) 17:1563 Trimble CL, Trimble EL (2003) Ovarian tumors of low malignant potential. Oncology (Huntingt) 17:1563
17.
Zurück zum Zitat Morice P, Camette S, El Hassan J (2001) Clinical outcomes and fertility after conservative treatment of ovarian borderline tumors. Fertil Steril 75:92PubMedCrossRef Morice P, Camette S, El Hassan J (2001) Clinical outcomes and fertility after conservative treatment of ovarian borderline tumors. Fertil Steril 75:92PubMedCrossRef
18.
Zurück zum Zitat Suh-Burgmann E (2006) Long-term outcomes following conservative surgery for borderline tumor of the ovary: a large population-based study. Gynecol Oncol 103:841PubMedCrossRef Suh-Burgmann E (2006) Long-term outcomes following conservative surgery for borderline tumor of the ovary: a large population-based study. Gynecol Oncol 103:841PubMedCrossRef
19.
Zurück zum Zitat Zanetta G, Rota S, Chiari S (2001) Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study. J Clin Oncol 19:2658PubMed Zanetta G, Rota S, Chiari S (2001) Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study. J Clin Oncol 19:2658PubMed
20.
Zurück zum Zitat Morice P, Camatte S, Rey A (2003) Prognostic factors for patients with advanced stage serous borderline tumours of the ovary. Ann Oncol 14:592PubMedCrossRef Morice P, Camatte S, Rey A (2003) Prognostic factors for patients with advanced stage serous borderline tumours of the ovary. Ann Oncol 14:592PubMedCrossRef
22.
Zurück zum Zitat Buttin BM, Herzog TJ, Powell MA, Rader JS (2002) Epithelial ovarian tumors of low malignant potential: the role of microinvasion. Obstet Gynecol 99:11PubMedCrossRef Buttin BM, Herzog TJ, Powell MA, Rader JS (2002) Epithelial ovarian tumors of low malignant potential: the role of microinvasion. Obstet Gynecol 99:11PubMedCrossRef
23.
Zurück zum Zitat Sood AK, Abu-Rustum NR, Barakat RR (2005) Fifth international conference on ovarian cancer: challenges and opportunities. Gynecol Oncol 97:916PubMedCrossRef Sood AK, Abu-Rustum NR, Barakat RR (2005) Fifth international conference on ovarian cancer: challenges and opportunities. Gynecol Oncol 97:916PubMedCrossRef
24.
Zurück zum Zitat Geomini P, Bremer G, Kruitwagen R, Mol BW (2005) Diagnostic accuracy of frozen section diagnosis of the adnexal mass: a meta-analysis. Gynecol Oncol 96:1PubMedCrossRef Geomini P, Bremer G, Kruitwagen R, Mol BW (2005) Diagnostic accuracy of frozen section diagnosis of the adnexal mass: a meta-analysis. Gynecol Oncol 96:1PubMedCrossRef
Metadaten
Titel
Complete lymph node dissection: is it essential for the treatment of borderline epithelial ovarian tumors?
verfasst von
Mine Kanat-Pektas
Mustafa Ozat
Tayfun Gungor
Izzet Sahin
Hakan Yalcin
Bulent Ozdal
Publikationsdatum
01.04.2011
Verlag
Springer-Verlag
Erschienen in
Archives of Gynecology and Obstetrics / Ausgabe 4/2011
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-010-1539-5

Weitere Artikel der Ausgabe 4/2011

Archives of Gynecology and Obstetrics 4/2011 Zur Ausgabe

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.